This site is intended for
Healthcare Providers Only

The EXPAREL® Difference

The EXPAREL® Difference

Treat Pain at the Source with Efficacy that Lasts for up to 72 Hours

EXPAREL is the only single-dose local analgesic that provides

  • Up to 72 hours of non-opioid analgesia with
  • Reduced or eliminated opioid requirements
  • Without the need for catheters and pumps

Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy and hemorrhoidectomy procedures.

Through 72 hours, EXPAREL demonstrated a significant reduction in pain and opioid use in a pivotal soft tissue trial.

click charts to enlarge

Reduction in pain and opioid use through 72 hours relative to placebo

In the same study, EXPAREL significantly delayed opioid use and eliminated opioid requirements altogether for 28% of EXPAREL patients compared to 10% of placebo patients.

The clinical benefit of the attendant decrease in opioid consumption was not determined.

click charts to enlarge

Lower Cumulative Pain Scores with EXPAREL up to 72 Hours

EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age.

Is EXPAREL Right for My Patients

Is EXPAREL Right for My Patients?

Find out if EXPAREL could meet a need in your practice. > More

These are not all of the potential important safety considerations for EXPAREL, please see the full Prescribing Information.

To report an adverse event, e-mail or dial 1-855-RX-EXPAREL (1-855-793-9727).

For medical inquiries related to EXPAREL, contact Medical Information at or 1-855-RX-EXPAREL (1-855-793-9727).


  1. Gorfine SR, Onel E, et al. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Diseases of the Colon & Rectum. 2011;54(12):1552-1559.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age.

Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL.

Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.

In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL administration were nausea, constipation, and vomiting. Please see the full Prescribing Information for EXPAREL.


Sign up to receive updates on EXPAREL.


First name*

Last name*


ZIP code*

Providing the optional information about you below enables us to provide information geared to your needs.


Yes, I would like to receive periodic updates about EXPAREL via e-mail. I agree to the Privacy Policy.

Thank you! Your registration is complete.

Sorry. There was an error submitting your request. Please try again at another time.

Sorry. The connection to the server was lost. Please try again at another time.



Your name:*

Your colleague's name:*

Your colleague's e-mail address:*

To learn about our use of your information and your rights, please consult our Privacy Policy.

Your email has been sent.
Thank you!

The email address you entered was invalid.

Unfortunately, your email could not be sent at this time.